Doudna’s new venture; Aclaris CEO to step down; Tome’s $114M liver disorder deal with Genevant

2024-01-16

基因疗法

Plus, news about Orion, Stalicla, Cyrano Therapeutics and Instil Bio:

Jennifer Doudna’s latest venture: Her lab published a study Thursday in Nature Biotechnology detailing how antibody fragments can be used to target virus-like particles with gene editing machinery to T cells. The fine print shows that Doudna and the study’s first author, Jenny Hamilton, co-founded Azalea Therapeutics, a genetic medicine delivery startup. Azalea has raised $10 million, according to a Forbes profile of founding scientist Connor Tsuchida. — Lei Lei Wu

Doudna’s new venture; Aclaris CEO to step down; Tome’s $114M liver disorder deal with Genevant

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构